PDL BioPharma Inc

PDL BioPharma — FY2017 Earnings Presentation

15 slides from PDL BioPharma's earnings presentation, Mar 8, 2018

  1. Slide 1: Fourth Quarter/Year End 2017 Financial Results Conference Call

    PDL Fourth Quarter/Year End 2017 Financial Results Conference Call March 8, 2018

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements, including PDL's expectations with respectto its future royalty revenues, expenses, net income, and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actua

  3. Slide 3: Building Value Through Investments

    Building Value Through Investments o Focused on growth in order to continue value creation for shareholders. o Pleased with PDL’s achievements to replace the revenues from the expired Queen et al patents. = Strategic decisions have enabled income generating assets to fuel PDL’s business of today. =

  4. Slide 4: Royalty Investments

    Royalty Investments o Royalties relating to Depomed have far exceeded our expectations. = Investment made in October 2013 for $240.5 million. = Have accumulated $308.5 million through December 2017. = Glumetza and its authorized generic account for bulk of returns. = Expect other Depomed products, i

  5. Slide 5: Noden Background

    Noden Background o Noden Pharma = Platform upon which to build a pharmaceutical company. = PDL now owns 100% of Noden companies. = Noden already has two products on the market—both indicated for hypertension. —Tekturna® and Tekturna HCT®, as they are known in the US, and Rasilez® and Rasilez HCT®, a

  6. Slide 6: Noden: Building Profitable Growth

    Noden: Building Profitable Growth o Reported revenues on the Noden products for Q417 of $25.1 million. > $14.5 million from US sales and $10.6 million from ROW. o In November 2017, Noden assumed commercialization of Rasilez and Rasilez HCT in Switzerland and the EU as we transitioned away from profi

  7. Slide 7: Tekturna & Tekturna HCT

    Tekturna & Tekturna HCT ly Revenu $in millions $9,000 oe $7.193 STARS $7,464 97-633. 344 $6.943 $7,000 -¢6-447 $6.565 $6.491 $6474 sei $5.73 $5.910 $5.847 $5.000 $4,000 $3,000 $2,000 $1.000 $ Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 was PDL

  8. Slide 8: Executing Targeted Patient-Type Strategy

    Executing Targeted Patient-Type Strategy ACE/ ARB Intolerant: SWITCH CCB Notat Goal: ADD

  9. Slide 9: Tekturna & Tekturna HCT Prescriptions

    Tekturna & Tekturna HCT Prescriptions Tekturna Prescription Data - All Strengths 5000 4500 SO SS SS LSS HSH So OO SS Hg gH se gh” gh” ge Bg PH HP” og Hh gH hh” oO” S” oh A Mh QP KP KP Kh aK AHH Kh oh XP XP? XH BP rr rt EE MEI OE EE 3 FM HW Source: IMS Xponent weekly data PDL

  10. Slide 10: Continued Progress at LENSAR

    Continued Progress at LENSAR o Achieved quarterly revenue record of $7.5 million. o Recently added two highly acclaimed board members. = William “Bill” J. Link, Ph.D. » Richard L. Lindstrom, M.D. o Acquired laser business unit of Precision Eye Services (PES). = Consolidates LENSAR’s customer base fo

  11. Slide 11: Termination of Proposal to Acquire Neos

    "1 Termination of Proposal to Acquire Neos In June 2017, PDL made a verbal all cash proposal to acquire all shares of Neos for $10/share, including the possibility to increase the offer with limited due diligence, which was rejected by the Neos Board several days later as not compelling or specific

  12. Slide 12: Building Value Through Investments

    Building Value Through Investments A-10N tas am avhev ares awe 9T-10N or-das sramr or-heve ore over ST-10N stds stam sth stew sever PDL's Book Value Per Share ld iS = nN o / G a2 = G rs) o a HON tos eran whew tre aoe eI-10N exdas st re 9 oO fe} 2 a] o a % o £ 3) i= o = o > x [e} fe} io yn eal a a Su

  13. Slide 13: Fourth Quarter 2017 Financials

    Fourth Quarter 2017 Financials Three Months Ended ‘Twelve Months Ended December 31. December 31. (In thousands, except per share amounts) 207 2016 2017 2016 Royalties from Queen et a. patents $453 § 15513 § 36415 _§ 166158 Royalty rights - change in fair value 30.103 28,068 162.327 16.196 Interest r

  14. Slide 14: Fourth Quarter 2017 Financials

    Fourth Quarter 2017 Financials Condensed consolidated balance sheet (unaudited) December 31, Cash, cash equivalents and investments u Total notes receivable Total royalty rights - at fair value Total assets Convertible notes payable Total stockholders's equity December 31, 2017 2016 $ 532,114 $ 242,

  15. Slide 15: Question and Answer Session

    PDL Question and Answer Session

PDL BioPharma — FY2017 Earnings Presentation on 6ix